| Strata Minerals Limited (SMX) ORDINARY FULLY PAID |
Materials |
$8 |
Application for quotation of securities - SMX
|
27 Feb 2026 9:50AM |
$0.022 |
$0.019 |
fallen by
13.64%
|
|
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$392 |
CY25 Full Year Financial Results Investor Presentation
|
27 Feb 2026 9:50AM |
$1.050 |
$1.165 |
risen by
10.95%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 10% compared to the previous corresponding period (PCP).
- Gross margin impacted by product sales mix in the Americas and tariff introductions in North America.
- Underlying EBITDA of $48.0 million was consistent with the PCP, but margins compressed to 16.5%.
- Gaming operations units totaled 6,091, a reduction from the previous year.
- Net debt position of $11.8 million at year-end, compared to a net cash position of $9.7 million the previous year.
- No dividends were paid to maintain liquidity and invest in product developments.
- The A-Star Raptor dual screen cabinet performed well in the APAC region.
- A $43.1 million goodwill impairment was recognized in North America.
- Income tax benefit of $25.2 million was recorded, driven by deferred tax asset recognition.
- The A-Star Raptor cabinet launched with strong market traction, with 1,829 units sold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ardea Resources Limited (ARL) ORDINARY FULLY PAID |
Materials |
$92 |
Trading Halt
|
27 Feb 2026 9:50AM |
$0.680 |
$0.420 |
fallen by
38.24%
|
|
ARL - Price-sensitive ASX Announcement
Full Release
Key Points
- Ardea Resources Limited (ASX: ARL) requested a trading halt.
- The trading halt is pending the release of an announcement related to an equity raising.
- The trading halt is effective until the start of normal trading on 3 March 2026, or until the company releases the announcement.
- ASX Compliance issued the trading halt.
- Ardea Resources Limited's business office is located in West Perth, Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maggie Beer Holdings Ltd (MBH) ORDINARY FULLY PAID |
Consumer Staple |
$24 |
1HFY26 Results Announcement
|
27 Feb 2026 9:49AM |
$0.081 |
$0.053 |
fallen by
34.57%
|
|
MBH - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax from continued operations increased by 68% to $398,000.
- Maggie Beer Products division sales increased by 4.6% due to focus on key sales channels.
- Operational and other savings of $2.2 million contributed to a total improvement of $3.4 million over the last 12 months.
- Strong balance sheet with $15.5 million in available liquidity, no debt, and $11.5 million in improved cash position.
- Hampers and Gifts Australia business remained profitable despite challenging market conditions.
- Unsolicited and non-binding offers received for the HGA business, under evaluation for potential business changes.
- Focus on improving gross margins and sales in key export markets for Maggie Beer Products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$99 |
Lumos Delivers Several Pivotal Milestones in 1H FY26
|
27 Feb 2026 9:49AM |
$0.255 |
$0.105 |
fallen by
58.82%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Secured US$317 million exclusive distribution agreement with PHASE Scientific.
- Completed FebriDx® CLIA waiver clinical study and FDA submission.
- Achieved full Medicare reimbursement recognition across U.S. MAC jurisdictions.
- Positive operating cash flow of $0.8 million, improving by $7.1 million over the prior period.
- Received US$2.75 million in non-dilutive grant funding.
- Initiated BARDA-funded CLIA waived paediatric study.
- Focused on securing FDA CLIA waiver for FebriDx® by the end of Q1 CY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Environmental Clean Technologies Limited (ECT) ORDINARY FULLY PAID |
Industrials |
$49 |
Notification of buy-back - ECT
|
27 Feb 2026 9:49AM |
$0.130 |
$0.110 |
fallen by
15.38%
|
|
| Maggie Beer Holdings Ltd (MBH) ORDINARY FULLY PAID |
Consumer Staple |
$24 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:49AM |
$0.081 |
$0.053 |
fallen by
34.57%
|
|
MBH - Price-sensitive ASX Announcement
Full Release
Key Points
- Maggie Beer Holdings Ltd reported a net profit of $0.4 million from continuing operations for the half-year ended 31 December 2025.
- The group experienced a slight revenue decline of 1.7% to $52.9 million compared to the previous corresponding period.
- Maggie Beer Products (MBP) saw a revenue growth of 4.6% with new product launches and increased sales across most retail customers.
- Hampers and Gifts Australia (HGA) faced challenges with a 4.8% revenue decline, impacted by competitive markets and website issues.
- Gross margin for the group remained flat at 50.0%, while HGA improved its gross margin to 56.5% due to reduced discounting.
- A strategic review of HGA was initiated following unsolicited approaches from external parties.
- The company raised $2.98 million through a share placement and an additional $2.3 million via a rights issue.
- The balance sheet remained strong with net assets of $39.0 million and a net cash position of $12.6 million as of 31 December 2025.
- No dividends were declared or paid during the financial period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$392 |
CY25 Full Year Financial Results 31.12.25
|
27 Feb 2026 9:49AM |
$1.050 |
$1.165 |
risen by
10.95%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit Before Tax of $21.1 million for CY25.
- Revenue increased by 10% to $290.8 million.
- Underlying EBITDA of $48.0 million.
- EBITDA margin decreased by 1.8%.
- International revenues accounted for 80% of total revenue.
- North America's revenue was $151.3 million.
- Asia Pacific revenue increased by 52%.
- Latin America/Europe revenue increased to $69.3 million.
- Online segment revenue decreased to $5.2 million.
- Non-cash impairment of $43.1 million recorded.
- Operating costs rose by 5.6%.
- Research & Development expenses increased by 1%.
- Operating cash outflows of $3.7 million.
- Increased borrowings resulted in a Debt/Equity ratio of 28%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Avenira Limited (AEV) ORDINARY FULLY PAID |
Materials |
$33 |
Proposed issue of securities - AEV
|
27 Feb 2026 9:48AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
| Ainsworth Game Technology Limited (AGI) ORDINARY FULLY PAID |
Consumer Discretionary |
$392 |
App4E & Annual Financial Report for Year Ended 31.12.25
|
27 Feb 2026 9:48AM |
$1.050 |
$1.165 |
risen by
10.95%
|
|
AGI - Price-sensitive ASX Announcement
Full Release
Key Points
- Ainsworth Game Technology Limited reported revenue of AUD 290.8 million for 2025.
- The company faced a net loss of AUD 19.2 million during this period.
- Revenue from North America, the largest market, decreased in contribution percentage.
- Online revenue fell due to the end of the exclusivity agreement with GAN.
- No dividends were declared for the year ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID |
Health Care |
$851 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:48AM |
$3.600 |
$2.280 |
fallen by
36.67%
|
|
CU6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant increase in losses from ordinary activities after tax.
- Net tangible assets per ordinary security increased to 62.6 cents.
- No dividends declared during the period.
- Winding up of Clarity Pharmaceuticals Europe SA.
- Financial statements reviewed by Grant Thornton with an unmodified opinion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$23 |
Notice under Section 708A(5)(e) of the Corps Act
|
27 Feb 2026 9:48AM |
$0.065 |
$0.076 |
risen by
16.92%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$23 |
Application for quotation of securities - NOX
|
27 Feb 2026 9:47AM |
$0.065 |
$0.076 |
risen by
16.92%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$99 |
Appendix 4D and Half Year Report
|
27 Feb 2026 9:47AM |
$0.255 |
$0.105 |
fallen by
58.82%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss increased to US$4.88 million.
- Revenues decreased by 2.9% to US$6.12 million.
- All revenues generated in the United States.
- Adjusted EBITDA loss increased due to investments.
- No dividends declared during the period.
- New loan facility for working capital introduced.
- 22 million performance rights granted to CEO.
- Directors believe the company will remain a going concern.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alara Resources Limited (AUQ) ORDINARY FULLY PAID |
Materials |
$43 |
Change of Company Secretary and Registered Address
|
27 Feb 2026 9:47AM |
$0.034 |
$0.047 |
risen by
38.24%
|
|
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$192 |
Dividend/Distribution - JYC
|
27 Feb 2026 9:47AM |
$5.270 |
$6.500 |
risen by
23.34%
|
|
| Swoop Holdings Limited (SWP) ORDINARY FULLY PAID |
Communication Services |
$28 |
Correction to H1FY26 Investor Briefing Announcement
|
27 Feb 2026 9:46AM |
$0.140 |
$0.089 |
fallen by
36.43%
|
|
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$175 |
Corporate Governance Statement and Appendix 4G
|
27 Feb 2026 9:46AM |
$8.870 |
$12.000 |
risen by
35.29%
|
|
| SRJ Technologies Group plc (SRJ) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$10 |
Preliminary Final Report
|
27 Feb 2026 9:46AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|
SRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Comprehensive loss of £3,519,269 for the year ended 31 December 2025.
- Significant issuance of new shares, impacting share capital.
- Acquisition of First Avenue General Contracting LLC for strategic regional opportunities.
- Financial adjustments and impacts from amortisation and foreign exchange.
- Detailed cash flow management including financing activities.
- Active management of tangible and intangible asset investments.
- Ongoing lease agreements and related party transactions.
- Focus on Middle East strategic opportunities post-acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$43 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:46AM |
$0.036 |
$0.037 |
risen by
2.78%
|
|
| Micro-X Limited (MX1) ORDINARY FULLY PAID |
Health Care |
$17 |
MX1 - December 2025 Half Year Results Presentation
|
27 Feb 2026 9:45AM |
$0.065 |
$0.022 |
fallen by
66.15%
|
|
MX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Micro-X is focused on delivering fast, accurate imaging to support stroke diagnosis in both hospital and pre-hospital settings.
- The company is working on a Head CT that is small, robust, and lightweight, designed to fit in ambulances.
- Their Head CT technology is capable of imaging smaller than 1mm bleeds, surpassing the target standard of 2mm.
- Micro-X has received significant funding, including $8M for stroke diagnosis and $4.4M for ambulance trials.
- The first human imaging trial site is activated at Royal Melbourne Hospital, with a pilot study set for 2Q 2026.
- Micro-X aims to conduct a pivotal study with 108 patients over six months to evaluate the Head CT's effectiveness in emergency decision-making.
- They have received a $4.4M grant to support the development of a stroke-capable ambulance prototype.
- Micro-X's Head CT is entering human imaging trials to support regulatory applications.
- The company is developing a market access roadmap for the Head CT, involving hospital trials and ambulance trials in South Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$402 |
Notification of buy-back - MMI
|
27 Feb 2026 9:45AM |
$0.064 |
$1.305 |
risen by
1,939.06%
|
|
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
H1 FY26 Results Presentation
|
27 Feb 2026 9:45AM |
$0.065 |
$3.500 |
risen by
5,284.62%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant revenue growth to $7.1 million, a 360% increase from prior comparable period.
- Strategic acquisitions: Tank Stream Labs and Planet Startup.
- Two-engine business model combining operating business and investment portfolio.
- Focus on services like fractional CFO, governance advice, and community engagement.
- Net assets increased to $18.2 million, up 35% from June 2025.
- Recurring revenue supports ongoing investment activities.
- Introduction of The Founders Union platform to unify founder services.
- Enhanced portfolio performance through disciplined investment and ecosystem integration.
- Emphasis on strategic partnerships and expanding service lines.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metro Mining Limited (MMI) ORDINARY FULLY PAID |
Materials |
$402 |
2025 Financial Results
|
27 Feb 2026 9:45AM |
$0.064 |
$1.305 |
risen by
1,939.06%
|
|
MMI - Price-sensitive ASX Announcement
Full Release
Key Points
- Metro Mining Limited announced its 2025 financial results with a net profit after tax of $142.3 million, reversing a prior year loss.
- The company achieved record shipments of 6.2 million Wet Metric Tonnes (WMT), a 9% increase year-on-year.
- Metro Mining is implementing an on-market share buy-back of up to 5% of its issued ordinary shares.
- A senior debt restructure extended the maturity period by nine months to December 2027.
- The company reported record underlying EBITDA of $72.9 million, a 96% improvement from the previous year.
- Metro Mining received foreign currency hedging gains of $35.4 million.
- Market guidance for 2026 is set at 6.6 to 7.1 million WMT, following the expansion strategy.
- The company has $183.9 million in available carry forward tax losses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zeus Resources Limited (ZEU) ORDINARY FULLY PAID |
Energy |
$5 |
Pause in Trading
|
27 Feb 2026 9:45AM |
$0.011 |
$0.006 |
fallen by
45.45%
|
|
ZEU - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX Market Release on 27 February 2026
- Zeus Resources Limited with Security Code: ZEU
- Announcement of a temporary pause in trading
- Trading pause pending a further announcement
- Compliance with ASX Listings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
